07:00 - 07:45 Satellite Symposium 5 – Biopas Launch of Omvoh®: the arrival of a new IL-23 inhibitor and new therapeutic perspectives for IBD in Brazil
Fernando Magro (Portugal)
Marcello Imbrizi |
| |
07:45 - 09:15 Block 5: Challenges of IBD – From Incidence to Daily Practice Strategy
Moderador(a)
07:45 - 08:00 Global and Latin American IBD Epidemiology: Evolution of Incidence and Prevalence
| | | 08:00 - 08:15 Colorectal Cancer Surveillance in IBD: Who, When, and How?
| | | 08:15 - 08:30 T2T in Daily Practice: Feasible in Latin America? Possible Solutions
| | | 08:30 - 08:45 Costs and Access to Advanced Therapies and System Sustainability
| | | 08:45 - 09:15 Discussion | | | |
| |
09:15 - 09:30 Fibrostenosing Crohn's Disease: Future Perspectives
Apresentador(a)
|
| |
09:30 - 09:45 Therapeutic Pipeline in IBD
Apresentador(a)
|
| |
09:45 - 10:10 Break – Booth Visit |
| |
10:10 - 10:55 Satellite Symposium 6 – Abbvie Beyond the response: Building value with sustained results from SKYRIZI® (risankizumab) in CD
Peter Bossuyt (BELGIUM)
Munique Kurtz |
| |
10:55 - 12:25 Block 6: Challenges in Crohn's Disease
Moderador(a)
10:55 - 11:10 The End of Step-Up? Systematic Advanced Therapy
| | | 11:10 - 11:25 Does Location Matter? Management of Colonic and Small Bowel CD
| | | 11:25 - 11:40 Multi-refractory DC: strategies after multiple failures
| | | 11:40 - 11:55 The End of the "Last Option": A New Era of Surgery in Crohn's Disease
| | | 11:55 - 12:25 Discussion | | | |
| |
12:25 - 14:00 BREAK |
| |
12:30 - 13:15 Satellite Symposium 7 – Johnson & Johnson IL-23 Inhibition in Ulcerative Colitis: lessons from clinical evidence
Anita Afzalii (USA)
Rogério Saad |
| |
13:15 - 14:00 Satellite Symposium 8 – Johnson & Johnson Remittance to persistence: rethinking the therapeutic event of RCU with golimumab
Rodrigo Gasparini
Henrique Dalmolin |
| |
14:00 - 15:30 Block 7: Holistic care in complex Crohn's disease
Moderador(a)
14:00 - 14:12 Surgical Treatment and Clinical Intractability: Current definition of intractability, timing, and surgical preparation
| | | 14:12 - 14:24 Ostomy and Quality of Life: Impact of the stoma on young patients, the role of stomatherapy, and social reintegration
| | | 14:24 - 14:36 Sexuality in Crohn's Disease: Impact on sexual function, dyspareunia vs. psychogenic dysfunction, and clinical management
| | | 14:36 - 14:48 Obesity: The paradox of post-treatment weight gain, obesity as a pro-inflammatory state, and the impact on the management of biologics
| | | 14:48 - 15:00 Mental Health: Gut-brain axis, psychiatric impact of stomas/Crohn's disease, and multidisciplinary care
| | | 15:00 - 15:30 Discussion | | | |
| |
15:30 - 15:45 Managing difficult to treat IBD patients
|
| |
15:45 - 16:15 Break – Booth Visit |
| |
16:15 - 17:00 Satellite Symposium 9 – Amgen |
| |
17:00 - 18:30 Block 8: IBD in Challenging Situations
Moderador(a)
17:00 - 17:15 IBD in the Elderly: Current Challenges
| | | 17:15 - 17:30 Pregnancy and IBD: Safe Management
| | | 17:30 - 17:45 VEO-IBD: Diagnostic and Therapeutic Challenges
| | | 17:45 - 18:00 Transition of Care
| | | 18:00 - 18:30 Discussion | | | |
| |
18:30 - 20:30 General Assembly |
| |
21:00 - 23:59 GEDIIB Institutional Activity |
| |